Creative Medical Technology Holdings (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, has entered into a securities purchase agreement. The agreement with several institutional investors to purchase more than 7.5 million shares of common stock or common stock equivalents in a private placement. The shares will be priced at market value. In addition, Creative Medical Technology will issue unregistered warrants to the investors, enabling them to purchase up to 15,111,112 shares of common stock. According to the agreement, those shares will be offered at $2.25 per share. The announcement noted that the warrants, which will expire five years after being issued, have an exercise price of $2 per share and are immediately exercisable. The company anticipates gross proceeds from the private placement to be approximately $17 million. According to the announcement, Roth Capital Partners acted as the sole placement agent for the offering, which closed on May 3, 2022.
For more information about the company, visit www.CreativeMedicalTechnology.com.
About Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings is a commercial-stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
